Concord Biotech Limited (CONCORDBIO.NS)
INR 1594.3
(-3.42%)
INR 1594.3
(-3.42%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 6.26 Billion INR | 27.13% |
| 2022 | 3.26 Billion INR | 33.84% |
| 2021 | 2.43 Billion INR | -20.51% |
| 2020 | 3.06 Billion INR | 58.19% |
| 2019 | 1.93 Billion INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 681 Million INR | 5.15% |
| 2023 Q2 | 1.1 Billion INR | 53.99% |
| 2023 Q4 | 1.29 Billion INR | 24.7% |
| 2023 Q3 | 1.03 Billion INR | -6.28% |
| 2023 FY | 4.15 Billion INR | 27.13% |
| 2023 Q1 | 717.89 Million INR | -42.6% |
| 2022 Q3 | 1.05 Billion INR | 315.04% |
| 2022 FY | 3.26 Billion INR | 33.84% |
| 2022 Q4 | 1.25 Billion INR | 18.6% |
| 2022 Q2 | 254.07 Million INR | 0.0% |
| 2021 FY | 2.43 Billion INR | -20.51% |
| 2020 FY | 3.06 Billion INR | 58.19% |
| 2019 FY | 1.93 Billion INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Biocon Limited | 50.83 Billion INR | 87.681% |
| Blue Jet Healthcare Limited | 3.37 Billion INR | -85.689% |
| Dishman Carbogen Amcis Limited | -413 Million INR | 1616.187% |
| Jubilant Ingrevia Limited | 2.93 Billion INR | -112.992% |
| Lyka Labs Limited | 29.13 Million INR | -21396.231% |
| Panacea Biotec Limited | - INR | -Infinity% |
| Piramal Pharma Limited | 4.31 Billion INR | -45.115% |
| SMS Lifesciences India Limited | 359.47 Million INR | -1641.958% |
| Supriya Lifescience Limited | 1.57 Billion INR | -298.425% |
| Syngene International Limited | 6.46 Billion INR | 3.187% |
| TAKE Solutions Limited | -213.49 Million INR | 3033.089% |
| Zota Health Care Limited | -129.79 Million INR | 4924.38% |